Molecular Biotechnology: From DNA Sequence to Therapeutic Protein
Therapeutic proteins have become a very valuable addition to the repertoire of drugs to treat patients with severe diseases. Therapeutic proteins differ in many aspects from classical, small molecule drugs. They differ, for example, in molecular size, uniformity of the active, production, purification, contaminations, side effects, stability, formulation, regulatory aspects, and price.
This chapter describes basic elements of the selection, design, cloning and production of biopharmaceuticals. The importance of the expression host in relation to specific post-translational modifications, such as the formation of disulfide bridges and glycosylation, is discussed. And finally, we describe the molecular biological aspects of the design and production of (humanized) monoclonal antibodies in cell culture.
KeywordsTherapeutic protein Expression host Post-translational modification PCR Humanized monoclonal antibody
- EvaluatePharma® World Preview 2017 (2017) Outlook to 2022. http://info.evaluategroup.com/rs/607-YGS-364/images/WP17.pdf. Accessed 3 Apr 2018.
- GAciarz A, Khatri NK, Velez-Superbie ML, Saaranen MJ, Uchida Y, Keshavarz-Moore E, Ruddock LW (2017) Efficient soluble expression of disulfide bonded proteins in the cytoplasm of Escherichia coli in fed batch fermentations on chemically defined minimal media. Microbio Cell Fact 16:108CrossRefGoogle Scholar
- Lodish H, Berk A, Kaiser CA, Krieger M, Scott MP (2007) Molecular cell biology, 6th edn. WH. Freeman & CO, New YorkGoogle Scholar
- Rosano GL, Ceccarelli EA (2014) Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol 5(172):1–17Google Scholar